The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.
Significant sensitivity to cisplatin-based chemotherapy is signaled by the presence of low expression of SMARCA4/BRG1 in patients with earlier-stage NSCLC. Low expression of SMARCA4/BRG1 was also linked to a poor prognosis.
Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.
An immunohistochemistry (IHC) test for rearrangements of the gene for anaplastic lymphoma kinase (ALK) receptor performed more accurately than another commonly used IHC assay, including reducing the rate of false positives.
Outcomes Are Comparable With Treatment Allocation Based on CGA or Performance Status and Age in Elderly Patients with NSCLCFebruary 18, 2016
Treatment allocation based on comprehensive geriatric assessment (CGA) did not improve treatment failure free survival or overall survival, but treatment toxicity was slightly reduced, in elderly patients with NSCLC.
Addition of bevacizumab to chemotherapy beyond disease progression may be effective in patients with advanced non-small cell lung cancer (NSCLC).
Younger age is associated with an increased likelihood of having a targetable genotype in patients with non-small cell lung cancer (NSCLC).
Treatment with stereotactic body radiotherapy (SBRT) was well-tolerated by patients whose non-small cell lung cancer (NSCLC) tumors were located centrally in the chest and who were not candidates for surgery.
Most patients with NSCLC that has metastasized to the brain have a dire prognosis. However, researchers have identified a subset of those patients who have a rare genetic mutation and are living significantly longer than patients without the mutation.
An analysis of an international, cooperative-led trial of patients with locally advanced NSCLC has shown that those who received IMRT had less severe lung toxicity and were able to better tolerate their chemotherapy, compared with patients who received 3-D CRT.
An international team of cancer researchers announced game-changing results in the treatment of certain lung cancers with nivolumab compared with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.
A panel of five serum microRNAs has been identified as a potential biomarker to diagnose early stage non-small cell lung cancer.
Patients with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection of all or part of the lung if combined with chemotherapy and radiation therapy.
Individuals with squamous non-small cell lung cancer (NSCLC) fared better when receiving nivolumab when compared to those receiving more standard chemotherapy, according to a recent clinical trial.
Stereotactic ablative radiotherapy (SABR) offers better overall survival than surgery in early lung cancerJune 02, 2015
Patients with operable stage I non-small cell lung cancer can achieve better overall survival rates if treated with stereotactic ablative radiotherapy (SABR) opposed to the current standard therapy.
Researchers urge for new targeted inhibitors and combinations to combat tumors' constant and varied molecular adaptation.
This developing technology allows serial monitoring to better gauge response to treatment and prognosis for patients with non-small cell lung cancer.
Research indicates that a known mutation in non-small cell lung cancer (NSCLC) is also present in small cell lung cancer, implying that some effective treatments for NSCLC can also be used on the more aggressive form of the disease.
Stereotactic body radiation therapy (SBRT) plus chemotherapy improves survival among patients with stage 4 lung cancerJanuary 20, 2015
Combining stereotactic body radiation therapy (SBRT) with a specific chemotherapy regimen more than doubled survival rates for certain patients with stage 4 lung cancer, according to recent research data.
An oral drug called ASP8273 caused tumor shrinkage in patients in a phase I clinical trial, according to research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Patients with non-small lung cancer (NSCLC) that received postoperative radiation therapy (PORT) lived an average of 4 months longer, when compared with patients who had the same disease progression and treatment criteria.
Treatment with the drug crizotinib has been effective for stopping lung tumor growth driven by rearrangements of the ROS1 gene.
EGFR mutations in circulating tumor DNA (ctDNA) can be used in place of tumor tissue in non-small cell lung cancer (NSCLC) diagnosticsSeptember 10, 2014
Epidermal growth factor receptor mutations found in ctDNA in the plasma of patients with advanced non-small cell lung cancer correlates well with the EGFR mutations from patient-matched tumor tissue DNA.
EGFR inhibitors are widely used to treat metastatic NSCLC; however, they can cause various adverse effects that differ from those caused by traditional intravenous chemotherapy.
A 10-year study shows that increased availability of better systemic chemotherapies and targeted therapies for patients with advanced non-small cell lung cancer coincides with increased usage of these therapies.
Lung cancer patients could receive more precise treatment, and their progress could be better tracked by using a new high-tech method of non-invasive medical imaging analysis, according to a new study.
Approximately half of all patients with a diagnosis of non-small cell lung cancer are age 70 years or older, yet elderly patients are not well represented in clinical trials.
Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.
New quantitative data suggests that 30% of the surgeries performed for non-small cell lung cancer patients in a community-wide clinical study were deemed unnecessary.
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system.
Sign Up for Free e-newsletters
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Shorter Duration of Cryotherapy as Effective as Standard Therapy Prior to HSCT for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- 9/11 Responders May Have Higher Head and Neck Cancer Risk
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|